A Phase 1/2, Open-Label, First-In-Human Trial Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Preliminary Antitumour Activity Of Odm-216 In Participants With Advanced Solid Tumours (BICIDES)
Principal Investigator
Dr Eileen Parkes
Contact us
Email: orh-tr.earlyphasenurses@nhs.net
IRAS number
1014309